logo
logo

Disc Medicine Announces $90 Million Series B Financing To Advance Portfolio Of Clinical-Stage Therapies For Hematologic Diseases

Sep 02, 2021•almost 4 years ago

Amount Raised

$90 Million

Round Type

series b

Cambridge

Description

Disc Medicine, a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for the treatment of serious and debilitating hematologic diseases, today announced a $90 million Series B financing from a leading syndicate of investors. The financing was led by OrbiMed with participation from new investors Arix Bioscience, Janus Henderson Investors, 5AM Ventures, Rock Springs Capital, Nantahala Capital Management, Willett Advisors, and Alexandria Venture Investments. Existing investors also participated in the financing, including Atlas Venture, Novo Holdings and Access Biotechnology.

Company Information

Company

Disc Medicine

Location

Cambridge, Maryland, United States

About

Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. We are building a unique portfolio of innovative, first-in-class therapeutic candidates based on fundamental pathways of red blood cell biology. Disc Medicine is committed to building a brighter future for patients who suffer from hematologic disease, ranging from severe orphan conditions to widely prevalent diseases. For more information, please visit www.discmedicine.com. SOURCE Disc Medicine

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech